Kura Oncology (KURA) Misses Q3 EPS by 10c

Kura Oncology (NASDAQ: KURA) reported Q3 EPS of ($0.85), $0.10 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $20.75 million versus the consensus estimate of $20.66 million.

For earnings history and earnings-related data on Kura Oncology (KURA) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• NV Gold closes final tranche of private placement, raising $1.4M
• Netcapital gets second Nasdaq notice over late financial filings